These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
380 related items for PubMed ID: 22345481
1. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD, Wyatt RT, Mascola JR, Poignard P, Burton DR. J Virol; 2012 Apr; 86(8):4394-403. PubMed ID: 22345481 [Abstract] [Full Text] [Related]
2. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. Feng Y, McKee K, Tran K, O'Dell S, Schmidt SD, Phogat A, Forsell MN, Karlsson Hedestam GB, Mascola JR, Wyatt RT. J Biol Chem; 2012 Feb 17; 287(8):5673-86. PubMed ID: 22167180 [Abstract] [Full Text] [Related]
8. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes. Tanaka K, Kuwata T, Alam M, Kaplan G, Takahama S, Valdez KPR, Roitburd-Berman A, Gershoni JM, Matsushita S. Retrovirology; 2017 Sep 22; 14(1):44. PubMed ID: 28938888 [Abstract] [Full Text] [Related]
9. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, Imamichi H, Doria-Rose N, Hoxie JA, Connors M, Shaw GM, Wyatt RT, Mascola JR. J Virol; 2012 May 22; 86(10):5844-56. PubMed ID: 22419808 [Abstract] [Full Text] [Related]
10. CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies. Gardner MR, Fellinger CH, Prasad NR, Zhou AS, Kondur HR, Joshi VR, Quinlan BD, Farzan M. J Virol; 2016 Sep 01; 90(17):7822-32. PubMed ID: 27334589 [Abstract] [Full Text] [Related]
11. HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice. Galkin A, Chen Y, Guenaga J, O'Dell S, Acevedo R, Steinhardt JJ, Wang Y, Wilson R, Chiang CI, Doria-Rose N, Grishaev AV, Mascola JR, Li Y. J Immunol; 2020 Mar 15; 204(6):1543-1561. PubMed ID: 32066595 [Abstract] [Full Text] [Related]
12. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies. Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT. J Virol; 2014 Dec 15; 88(24):14002-16. PubMed ID: 25253346 [Abstract] [Full Text] [Related]
13. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes. Chen Y, Wilson R, O'Dell S, Guenaga J, Feng Y, Tran K, Chiang CI, Arendt HE, DeStefano J, Mascola JR, Wyatt RT, Li Y. J Immunol; 2016 Nov 15; 197(10):3982-3998. PubMed ID: 27815444 [Abstract] [Full Text] [Related]
14. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. Zhang MY, Yuan T, Li J, Rosa Borges A, Watkins JD, Guenaga J, Yang Z, Wang Y, Wilson R, Li Y, Polonis VR, Pincus SH, Ruprecht RM, Dimitrov DS. PLoS One; 2012 Nov 15; 7(9):e44241. PubMed ID: 22970187 [Abstract] [Full Text] [Related]
15. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. Zwick MB, Kelleher R, Jensen R, Labrijn AF, Wang M, Quinnan GV, Parren PW, Burton DR. J Virol; 2003 Jun 15; 77(12):6965-78. PubMed ID: 12768015 [Abstract] [Full Text] [Related]
16. Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18. Gift SK, Zentner IJ, Schön A, McFadden K, Umashankara M, Rajagopal S, Contarino M, Duffy C, Courter JR, Zhang MY, Gershoni JM, Cocklin S, Dimitrov DS, Smith AB, Freire E, Chaiken IM. Biochemistry; 2011 Apr 12; 50(14):2756-68. PubMed ID: 21351734 [Abstract] [Full Text] [Related]
17. The molecular mechanism of two coreceptor binding site antibodies X5 and 17b neutralizing HIV-1: Insights from molecular dynamics simulation. Zhang Y, Guo J, Huang L, Tian J, Yao X, Liu H. Chem Biol Drug Des; 2018 Jul 12; 92(1):1357-1365. PubMed ID: 29624884 [Abstract] [Full Text] [Related]
18. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Tran K, Poulsen C, Guenaga J, de Val N, Wilson R, Sundling C, Li Y, Stanfield RL, Wilson IA, Ward AB, Karlsson Hedestam GB, Wyatt RT. Proc Natl Acad Sci U S A; 2014 Feb 18; 111(7):E738-47. PubMed ID: 24550318 [Abstract] [Full Text] [Related]
19. Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site. Utachee P, Isarangkura-na-ayuthaya P, Tokunaga K, Ikuta K, Takeda N, Kameoka M. Retrovirology; 2014 Apr 23; 11():32. PubMed ID: 24758333 [Abstract] [Full Text] [Related]
20. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, Burton DR. J Virol; 1994 Aug 23; 68(8):4821-8. PubMed ID: 7518527 [Abstract] [Full Text] [Related] Page: [Next] [New Search]